BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BIIB122 / DNL151 (LRRK2 inhibitor) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BIIB122 / DNL151 (LRRK2 inhibitor)\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06602193-1609@assetmemo.bio
DTSTAMP:20261121T010016Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:BIIB122 / DNL151 (LRRK2 inhibitor): Phase 2 readout est. (NCT066021
 93)
DESCRIPTION:BIIB122 / DNL151 (LRRK2 inhibitor)\, phase 2\, Parkinson's Dise
 ase.\nStudy: Safety and Pharmacodynamic Effects of BIIB122 in Participants
  With LRRK2-Associated Parkinson's Disease (LRRK2-PD)\nEstimated primary c
 ompletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/biib122-dnl151-lrrk2-inhibitor#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06602193
URL:https://assetmemo.bio/drug/biib122-dnl151-lrrk2-inhibitor#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
